Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Saved in:
| Title: | Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. |
|---|---|
| Authors: | Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany., Vender R; Dermatrials Research Inc., Hamilton, ON, Canada., de Rie MA; Department of Dermatology, Amsterdam University Medical Centres, Amsterdam, the Netherlands., Conrad C; Department of Dermatology, Lausanne University Hospital, Switzerland., Pariser DM; Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA.; Virginia Clinical Research, Inc., Norfolk, VA, USA., Strober B; Yale University, New Haven, CT, USA.; Central Connecticut Dermatology Research, Cromwell, CT, USA., Vanvoorden V; UCB Pharma, Brussels, Belgium., Wang M; UCB Pharma, Raleigh, NC, USA., Madden C; UCB Pharma, Raleigh, NC, USA., de Cuyper D; UCB Pharma, Brussels, Belgium., Kimball AB; Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA. |
| Source: | The British journal of dermatology [Br J Dermatol] 2023 Jan 23; Vol. 188 (1), pp. 22-31. |
| Publication Type: | Randomized Controlled Trial; Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2133 |
|---|---|
| DOI: | 10.1093/bjd/ljac021 |
